How did I miss this 2 weeks ago? I know, too much noise on the board.
The outline of the story is that Intermune is selling the only drug ever shown to alter the course of Idiopathic Pulmonary Fibrosis, a disease that is always fatal with a 2-6 year course (and there have been a lot of failed drugs, including an earlier one from Intermune). Unfortunately, the drug only slows progression, it doesn't reverse damage or make people feel better quickly. Uptake is slow, which is depressing stock price, but ultimately a large fraction of the roughly 200K IPF patients in Europe and the US are likely to use Esbriet.
There are a lot of imaginable catalysts, but the two most likely to actually affect stock price are financial break-even and US approval, both probably around 18 months off. The company has cash to operate until then, but financing for a US drug introduction is not in place. There is concern that such financing might be very dilutive.
You have asked all the questions that are answered when one does basic research. If you go back to company site and look at press releases and match them up with stock moves, you will get the answers you want. Probably not realistic to expect those here to spell out chapter and verse what we all have done over the years.